A New, Cheaper COVID-19 Vaccine Developed

A new vaccine has been developed against the COVID-19 virus. According to the news of The Guardian, scientists from the Texas Children’s Hospital Vaccine Development Center Dr. Peter Hotez and Dr. Maria Bottazzi, injured by yeast COVID-19 vaccine announced their development. Working on Sars and Mers viruses and developing a vaccine prototype since 2011, the team developed a vaccine based on these prototypes. ‘Corbevax’ gave his name.

They said that they would not obtain a patent for the new COVID-19 vaccine they developed and therefore the vaccine ‘special’ Stating that Dr. Bottasia; He stated that more than 60 vaccines have been developed based on the same technology. Regarding the decision not to obtain a patent, Bottazzi said, “We want to do the world a favor. It was the right thing to do, and morally we should have done it. We decided without even blinking an eye” recorded as.

Corbevax will be more affordable than other COVID-19 vaccines

Bottazzi for the Corvebax vaccine, which is based on the principle that a real COVID-19 spike protein is inserted into the yeast cell, copying the basic protein and then joining the immune system, “We make the protein directly and synthetically, using a yeast system in the laboratory. We make the yeast develop the same protein as in the virus. In this way, the body to immunity we deliver” used the phrases.

Similar to the Hepatitis B vaccine, clinical test results for Corbevax, developed with yeast, have not yet been released due to resource constraints; However, in the statement made by the hospital, the vaccine is against the original Covid virus. 90 percent, if against the Delta variant 80 percent reported to be effective. Tests are ongoing to understand how Corbevax affects the Omicron variant.

Bottazzi noted that they could not get any help from government institutions for financing; He appealed to the benefactors to continue the work. In addition, the Corbevax vaccine is much better than the current commercially available COVID-19 vaccines. affordable will be reported.